Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1993 Jan;91(1):301–307. doi: 10.1172/JCI116186

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

M A Nauck 1, M M Heimesaat 1, C Orskov 1, J J Holst 1, R Ebert 1, W Creutzfeldt 1
PMCID: PMC330027  PMID: 8423228

Abstract

In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed to compare insulinotropic actions of exogenous incretin hormones (gastric inhibitory peptide [GIP] and glucagon-like peptide 1 [GLP-1] [7-36 amide]) in nine type-2 diabetic patients (fasting plasma glucose 7.8 mmol/liter; hemoglobin A1c 6.3 +/- 0.6%) and in nine age- and weight-matched normal subjects. Synthetic human GIP (0.8 and 2.4 pmol/kg.min over 1 h each), GLP-1 [7-36 amide] (0.4 and 1.2 pmol/kg.min over 1 h each), and placebo were administered under hyperglycemic clamp conditions (8.75 mmol/liter) in separate experiments. Plasma GIP and GLP-1 [7-36 amide] concentrations (radioimmunoassay) were comparable to those after oral glucose with the low, and clearly supraphysiological with the high infusion rates. Both GIP and GLP-1 [7-36 amide] dose-dependently augmented insulin secretion (insulin, C-peptide) in both groups (P < 0.05). With GIP, the maximum effect in type-2 diabetic patients was significantly lower (by 54%; P < 0.05) than in normal subjects. With GLP-1 [7-36 amide] type-2 diabetic patients reached 71% of the increments in C-peptide of normal subjects (difference not significant). Glucagon was lowered during hyperglycemic clamps in normal subjects, but not in type-2 diabetic patients, and further by GLP-1 [7-36 amide] in both groups (P < 0.05), but not by GIP. In conclusion, in mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity. It also lowers glucagon concentrations.

Full text

PDF
304

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buchan A. M., Polak J. M., Capella C., Solcia E., Pearse A. G. Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry. 1978 Jun 2;56(1):37–44. doi: 10.1007/BF00492251. [DOI] [PubMed] [Google Scholar]
  2. Creutzfeldt W., Ebert R., Nauck M., Stöckmann F. Disturbances of the entero-insular axis. Scand J Gastroenterol Suppl. 1983;82:111–119. [PubMed] [Google Scholar]
  3. Creutzfeldt W. The incretin concept today. Diabetologia. 1979 Feb;16(2):75–85. doi: 10.1007/BF01225454. [DOI] [PubMed] [Google Scholar]
  4. DeFronzo R. A. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988 Jun;37(6):667–687. doi: 10.2337/diab.37.6.667. [DOI] [PubMed] [Google Scholar]
  5. DeFronzo R. A., Tobin J. D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979 Sep;237(3):E214–E223. doi: 10.1152/ajpendo.1979.237.3.E214. [DOI] [PubMed] [Google Scholar]
  6. Deacon C. F., Schleser-Mohr S., Ballmann M., Willms B., Conlon J. M., Creutzfeldt W. Preferential release of proinsulin relative to insulin in non-insulin-dependent diabetes mellitus. Acta Endocrinol (Copenh) 1988 Dec;119(4):549–554. doi: 10.1530/acta.0.1190549. [DOI] [PubMed] [Google Scholar]
  7. Dupre J., Ross S. A., Watson D., Brown J. C. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973 Nov;37(5):826–828. doi: 10.1210/jcem-37-5-826. [DOI] [PubMed] [Google Scholar]
  8. Elahi D., Andersen D. K., Muller D. C., Tobin J. D., Brown J. C., Andres R. The enteric enhancement of glucose-stimulated insulin release. The role of GIP in aging, obesity, and non-insulin-dependent diabetes mellitus. Diabetes. 1984 Oct;33(10):950–957. doi: 10.2337/diab.33.10.950. [DOI] [PubMed] [Google Scholar]
  9. Füessl H. S., Yiangou Y., Ghatei M. A., Goebel F. D., Bloom S. R. Effect of synthetic human glucose-dependent insulinotropic polypeptide (hGIP) on the release of insulin in man. Eur J Clin Invest. 1990 Oct;20(5):525–529. doi: 10.1111/j.1365-2362.1990.tb01896.x. [DOI] [PubMed] [Google Scholar]
  10. Gutniak M., Orskov C., Holst J. J., Ahrén B., Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992 May 14;326(20):1316–1322. doi: 10.1056/NEJM199205143262003. [DOI] [PubMed] [Google Scholar]
  11. Holst J. J. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J. 1982 Dec 1;207(3):381–388. doi: 10.1042/bj2070381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Holst J. J., Orskov C., Nielsen O. V., Schwartz T. W. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 1987 Jan 26;211(2):169–174. doi: 10.1016/0014-5793(87)81430-8. [DOI] [PubMed] [Google Scholar]
  13. Jones I. R., Owens D. R., Moody A. J., Luzio S. D., Morris T., Hayes T. M. The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia. 1987 Sep;30(9):707–712. doi: 10.1007/BF00296993. [DOI] [PubMed] [Google Scholar]
  14. Jörnvall H., Carlquist M., Kwauk S., Otte S. C., McIntosh C. H., Brown J. C., Mutt V. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP). FEBS Lett. 1981 Jan 26;123(2):205–210. doi: 10.1016/0014-5793(81)80288-8. [DOI] [PubMed] [Google Scholar]
  15. Kawai K., Suzuki S., Ohashi S., Mukai H., Ohmori H., Murayama Y., Yamashita K. Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinology. 1989 Apr;124(4):1768–1773. doi: 10.1210/endo-124-4-1768. [DOI] [PubMed] [Google Scholar]
  16. Komatsu R., Matsuyama T., Namba M., Watanabe N., Itoh H., Kono N., Tarui S. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes. 1989 Jul;38(7):902–905. doi: 10.2337/diab.38.7.902. [DOI] [PubMed] [Google Scholar]
  17. Krarup T., Holst J. J. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept. 1984 Sep;9(1-2):35–46. doi: 10.1016/0167-0115(84)90005-3. [DOI] [PubMed] [Google Scholar]
  18. Krarup T. Immunoreactive gastric inhibitory polypeptide. Endocr Rev. 1988 Feb;9(1):122–134. doi: 10.1210/edrv-9-1-122. [DOI] [PubMed] [Google Scholar]
  19. Krarup T., Saurbrey N., Moody A. J., Kühl C., Madsbad S. Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus. Metabolism. 1987 Jul;36(7):677–682. doi: 10.1016/0026-0495(87)90153-3. [DOI] [PubMed] [Google Scholar]
  20. Kreymann B., Williams G., Ghatei M. A., Bloom S. R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987 Dec 5;2(8571):1300–1304. doi: 10.1016/s0140-6736(87)91194-9. [DOI] [PubMed] [Google Scholar]
  21. Kuzio M., Dryburgh J. R., Malloy K. M., Brown J. C. Radioimmunoassay for gastric inhibitory polypeptide. Gastroenterology. 1974 Mar;66(3):357–364. [PubMed] [Google Scholar]
  22. Mojsov S., Weir G. C., Habener J. F. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987 Feb;79(2):616–619. doi: 10.1172/JCI112855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Moody A. J., Thim L., Valverde I. The isolation and sequencing of human gastric inhibitory peptide (GIP). FEBS Lett. 1984 Jul 9;172(2):142–148. doi: 10.1016/0014-5793(84)81114-x. [DOI] [PubMed] [Google Scholar]
  24. Nathan D. M., Schreiber E., Fogel H., Mojsov S., Habener J. F. Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care. 1992 Feb;15(2):270–276. doi: 10.2337/diacare.15.2.270. [DOI] [PubMed] [Google Scholar]
  25. Nauck M. A., Homberger E., Siegel E. G., Allen R. C., Eaton R. P., Ebert R., Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986 Aug;63(2):492–498. doi: 10.1210/jcem-63-2-492. [DOI] [PubMed] [Google Scholar]
  26. Nauck M., Schmidt W. E., Ebert R., Strietzel J., Cantor P., Hoffmann G., Creutzfeldt W. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab. 1989 Sep;69(3):654–662. doi: 10.1210/jcem-69-3-654. [DOI] [PubMed] [Google Scholar]
  27. Nauck M., Stöckmann F., Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986 Jan;29(1):46–52. doi: 10.1007/BF02427280. [DOI] [PubMed] [Google Scholar]
  28. Orskov C., Bersani M., Johnsen A. H., Højrup P., Holst J. J. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem. 1989 Aug 5;264(22):12826–12829. [PubMed] [Google Scholar]
  29. Orskov C., Holst J. J., Nielsen O. V. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988 Oct;123(4):2009–2013. doi: 10.1210/endo-123-4-2009. [DOI] [PubMed] [Google Scholar]
  30. Orskov C., Holst J. J. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest. 1987 Apr;47(2):165–174. [PubMed] [Google Scholar]
  31. Orskov C., Jeppesen J., Madsbad S., Holst J. J. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest. 1991 Feb;87(2):415–423. doi: 10.1172/JCI115012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Perley M. J., Kipnis D. M. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest. 1967 Dec;46(12):1954–1962. doi: 10.1172/JCI105685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schmidt W. E., Siegel E. G., Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia. 1985 Sep;28(9):704–707. doi: 10.1007/BF00291980. [DOI] [PubMed] [Google Scholar]
  34. Shima K., Hirota M., Ohboshi C. Effect of glucagon-like peptide-1 on insulin secretion. Regul Pept. 1988 Aug;22(3):245–252. doi: 10.1016/0167-0115(88)90037-7. [DOI] [PubMed] [Google Scholar]
  35. Shuster L. T., Go V. L., Rizza R. A., O'Brien P. C., Service F. J. Incretin effect due to increased secretion and decreased clearance of insulin in normal humans. Diabetes. 1988 Feb;37(2):200–203. doi: 10.2337/diab.37.2.200. [DOI] [PubMed] [Google Scholar]
  36. Suzuki S., Kawai K., Ohashi S., Mukai H., Murayama Y., Yamashita K. Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas. Diabetes. 1990 Nov;39(11):1320–1325. doi: 10.2337/diab.39.11.1320. [DOI] [PubMed] [Google Scholar]
  37. Tillil H., Shapiro E. T., Miller M. A., Karrison T., Frank B. H., Galloway J. A., Rubenstein A. H., Polonsky K. S. Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol. 1988 Mar;254(3 Pt 1):E349–E357. doi: 10.1152/ajpendo.1988.254.3.E349. [DOI] [PubMed] [Google Scholar]
  38. Varndell I. M., Bishop A. E., Sikri K. L., Uttenthal L. O., Bloom S. R., Polak J. M. Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. J Histochem Cytochem. 1985 Oct;33(10):1080–1086. doi: 10.1177/33.10.3900195. [DOI] [PubMed] [Google Scholar]
  39. Weir G. C., Mojsov S., Hendrick G. K., Habener J. F. Glucagonlike peptide I (7-37) actions on endocrine pancreas. Diabetes. 1989 Mar;38(3):338–342. doi: 10.2337/diab.38.3.338. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES